References

Arrain Y, Masud T. Bisphosphonates and osteonecrosis of the jaw – current thoughts. Dent Update. 2009; 36:415-419
American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw. http://www.aaoms.org/docs/position_papers/bronj_update.pdf
Khan AA, Sandor GK, Dore E Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw. J Rheumatol. 2008; 35:1391-1397
Khamaisi M, Regev E, Yarom N Possible association between diabetes and bisphosphonate associated osteonecrosis. J Clin Endocrinol Metab. 2007; 92
Wessel JH, Dobson TB, Zavras Al. Zolendronate, smoking and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg. 2008; 66
Kanis JA, Johnell O, Oden A Smoking and fracture risk: a meta analysis. Osteoporosis Int. 2005; 16:155-162
Gralow JR, Biermann JS, Farooki A NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009; 7:S1-S32
Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticosteroid side effects. Int J Dermatol. 2010; 49:239-248
McLeod NMH, Patel P, Kusanale A Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg. 2011; 49:335-342
Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010; 136:1117-1124
Sambrook PN, Chen JS, Simpson JM Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust. 2010; 193:154-156
Almubarak H, Jones A, Chaisuparat R Zolendronic Acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog. 2011; 10
Di Salvatore M, Orlandi A, Babala C Anti-tumour and anti-angiogenetic effects of zolendronic acid on human non-small cell lung cancer line. Cell Prolif. 2011; 44:139-146
Tepos E, Croucher Pl, Garcia-Sanz R The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009; 20:1303-1317
SDCEP>Guidance> Bisphosphonates. http://www.sdcep.org.uk/index.aspx?o=3017
BDA (British Dental Association). Bisphosphonates. http://www.bda.org/pct-healthbody/…/bisphosphonates.aspx-
Arrain Y, Masud T. Recent recommendations on bisphosphonate-associated osteonecrosis of the jaw. Dent Update. 2008; 35:238-240
Sambrook P, Olver l, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aus Fam Physician. 2006; 35:801-803
Almazrooa SA, Woo S. Bisphosphonate and non-bisphosphonate associated osteonecrosis of the jaw. J Am Dent Assoc. 2009; 140:864-875
Orhan K, Bayindir H, Aksoy S Numb chin syndrome as a manifestation of possible breast cancer metastasis around dental implants. J Craniofac Surg. 2011; 22:942-945
Marx RE.Chicago: Quintessence Publishing Co Inc; 2007
Kunchur R, Need A, Hughes T. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67:1167-1173
Kim RH, Lee RS, William D. Bisphosphonates induce senescence in normal human oral keratinocytes. J Dent Res. 2011; 90:810-816
Aguire Jl, Altman MK, Vanegas SM Effects of alendronate on bone healing after tooth extraction in rats. Oral Dis. 2010; 16:674-685
Wehrhan F, Stockman P, Nkenke E Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral Surg Oral Med Oral Pathol Endodont. 2011; 112:216-221
Hokugo A, Christensen R, Chung EM Increased prevalence of bisphosphonate related osteonecrosis of the jaw with vitamin deficiency in rats. J Bone Miner Res. 2010; 25:1337-1349
Fedele S, Porter SR, D'Aiuto F Non-exposed variant of bisphosphonate associated osteonecrosis of the jaw: a case series. Am J Med. 2010; 123:1060-1064
Junquera L, Gallego L. Non exposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?. J Oral Maxillofac Surg. 2008; 66
Hutchinson M, O'Ryan F, Chavez V. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg. 2010; 68:2232-2240
Morgan G, Davies F, Gregory W Evaluating the effects of zolendronic acid (zol) on the overall survival (os) in patients (pts) with multiple myeloma (MM). Results of the Medical Research Council (MRC) Myeloma IX Study. J Clin Oncol. 2010; 28
Terpos E, Berenson J, Cook RJ Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia. 2010; 24:1043-1049
Gnant M, Harbeck N, Tomssen C. St Gallen 2011: Summary of the Consensus Discussion. Breast care. 2011; 6:136-141
Miksad RA, Lai KC, Dobson TB. Quality of life implications of bisphosphonate associated osteonecrosis of the jaw. Oncologist. 2011; 16:121-132
Black DM, Schwartz AV, Ensrud KE Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. J Am Med Assoc. 2006; 296:2927-2938
Phillips JM, Thibodeaux JD, Nathan CA Skull base osteomyelitis and bisphosphonate use in multiple myeloma: report of two cases and literature review. Laryngoscope. 2010; 120
Stopeck AT, Lipton A, Brody JJ. Denosumab compared with zolendronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28:5132-5139
Fizazi K, Carducci M, Smith M. Treatment of bone metastases in men with castration-resistant prostate cancer: a randomised double-blind study. Lancet. 2011; 5:(9768)813-822

A current update on osteonecrosis of the jaw and bisphosphonates

From Volume 38, Issue 10, December 2011 | Pages 672-678

Authors

Yazdana Arrain

BDS, DRDP

Clinical Lecturer in Restorative Dentistry, University of Birmingham School of Dentistry, St Chad's Queensway, Birmingham B4 6NN

Articles by Yazdana Arrain

Tahir Masud

MA(Oxon), MBBS(Lond), MSc(Nott), FRCP

Professor of Musculoskeletal Gerontology, University of Derby and Consultant Physician, Nottingham University Hospitals NHS Trust, Hucknell Road, Nottingham, NG5 1PB, UK

Articles by Tahir Masud

Abstract

Bisphosphonates are effective drugs used to treat important medical conditions affecting the skeleton, such as malignancy and osteoporosis. Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a rare but painful condition that can affect quality of life. Healthcare professionals need to be aware of this potential side-effect of bisphosphonates, as well as ways to minimize its occurrence.

Clinical Relevance: This review addresses the definitions of BONJ, differential diagnosis and staging, prevention and also discusses a recently recognized non-exposed variant of BONJ. The possibility that a recently introduced anti-resorptive agent, denosumab, which is not a bisphosphonate, may cause jaw osteonecrosis is also discussed.

Article

The bisphosphonate group of drugs are pyrophosphate analogues. They have a high affinity to bone and are taken up by osteoclasts during natural bone resorption. Bisphosphonates work by acting on osteoclast function to reduce bone resorption.1 They are important in treating many conditions such as osteoporosis, osteogenesis imperfecta, Paget's disease, skeletal events associated with metastatic cancer, hypercalcaemia, primary hyperparathyroidism and bone cancers such as Ewings Sarcoma (second most common bone cancer in young adolescents). As more research has been performed on bisphosphonates, their applications for use have increased. Consequently, general dental practitioners, dental hygienists and other healthcare workers may come across an increasing number of patients prescribed these drugs. Since bisphosphonates have been associated with osteonecrosis of the jaw (BONJ), it is essential that the management of patients on bisphosphonates is understood, the higher risk patient groups are identified and the risk of BONJ is minimized.

Register now to continue reading

Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Up to 2 free articles per month
  • New content available